{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:03:29Z","timestamp":1789495409077,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"DOI":"10.1007\/s40273-026-01666-5","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:17:48Z","timestamp":1789492668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Systematic Review of Reporting of Validation Efforts for Cancer Health Economic Decision Models"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1004-5739","authenticated-orcid":false,"given":"Pingping","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7829-7334","authenticated-orcid":false,"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1798-4671","authenticated-orcid":false,"given":"Yihe","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0367-6369","authenticated-orcid":false,"given":"Hualing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1507-0257","authenticated-orcid":false,"given":"Huayu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-9724","authenticated-orcid":false,"given":"Hongchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"6","key":"1666_CR1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jval.2012.06.016","volume":"15","author":"M Roberts","year":"2012","unstructured":"Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force\u20142. Value Health. 2012;15(6):804\u201311.","journal-title":"Value Health"},{"issue":"6","key":"1666_CR2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","volume":"15","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force\u20147. Value Health. 2012;15(6):843\u201350.","journal-title":"Value Health"},{"issue":"4","key":"1666_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349\u201361.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"1666_CR4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-024-01364-0","volume":"42","author":"I Corro Ramos","year":"2024","unstructured":"Corro Ramos I, Feenstra T, Ghabri S, Al M. Evaluating the validation process: embracing complexity and transparency in health economic modelling. Pharmacoeconomics. 2024;42(7):715\u20139.","journal-title":"Pharmacoeconomics"},{"key":"1666_CR5","unstructured":"Coordination Group on Health Technology Assessment (HTACG). Methodological guideline for quantitative evidence synthesis: direct and indirect comparisons. 2024. https:\/\/health.ec.europa.eu\/document\/download\/4ec8288e-6d15-49c5-a490-d8ad7748578f_en?filename=hta_methodological-guideline_direct-indirect-comparisons_en.pdf. Accessed 7 July 2026."},{"key":"1666_CR6","volume-title":"Developing a protocol for observational comparative effectiveness research: a user\u2019s guide","author":"Agency for Healthcare Research and Quality (US).","year":"2013","unstructured":"Agency for Healthcare Research and Quality (AHRQ). Developing a protocol for observational comparative effectiveness research: a user\u2019s guide.\u00a0Rockville (MD): Agency for Healthcare Research and Quality (US); 2013.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK126190\/. Accessed 1 Oct 2026."},{"key":"1666_CR7","unstructured":"Faria R, Alava MH, Manca A, Wailoo AJ. NICE DSU Technical Support Document 17: the use of observational data to inform estimates of treatment effectiveness for Technology Appraisal: methods for comparative individual patient data. 2015. https:\/\/sheffield.ac.uk\/sites\/default\/files\/2022-02\/TSD17-DSU-Observational-data-FINAL.pdf. Accessed 2 Jul 2026."},{"key":"1666_CR8","unstructured":"Davis S, Stevenson M, Tappenden P, Wailoo A. NICE DSU Technical Support Document 15: cost-effectiveness modelling using patient-level simulation. 2014. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310370\/pdf\/Bookshelf_NBK310370.pdf. Accessed 2 Jul 2026."},{"issue":"10","key":"1666_CR9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s40273-014-0186-2","volume":"32","author":"P Tappenden","year":"2014","unstructured":"Tappenden P, Chilcott JB. Avoiding and identifying errors and other threats to the credibility of health economic models. Pharmacoeconomics. 2014;32(10):967\u201379.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1666_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40273-018-0711-9","volume":"37","author":"S Ghabri","year":"2019","unstructured":"Ghabri S, Stevenson M, M\u00f6ller J, Caro JJ. Trusting the results of model-based economic analyses: is there a pragmatic validation solution? Pharmacoeconomics. 2019;37(1):1\u20136.","journal-title":"Pharmacoeconomics"},{"key":"1666_CR11","first-page":"1","volume":"3","author":"D Radeva","year":"2020","unstructured":"Radeva D, Hopkin G, Mossialos E, Borrill J, Osipenko L, Naci H. Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisals. Int J Technol Assess Health Care. 2020;3:1\u20136.","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"1666_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40273-021-01008-7","volume":"39","author":"B Schwander","year":"2021","unstructured":"Schwander B, Nuijten M, Evers S, Hiligsmann M. Replication of published health economic obesity models: assessment of facilitators, hurdles and reproduction success. Pharmacoeconomics. 2021;39(4):433\u201346.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1666_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-025-00772-3","volume":"5","author":"JO Oguta","year":"2025","unstructured":"Oguta JO, Breeze P, Wambiya E, Kibe P, Akoth C, Otieno P, et al. Application of decision analytic modelling to cardiovascular disease prevention in Sub-Saharan Africa: a systematic review. Commun Med. 2025;5(1):46.","journal-title":"Commun Med"},{"key":"1666_CR14","volume-title":"AHRQ methods for effective health care. Modeling and simulation in the context of health technology assessment: review of existing guidance, future research needs, and validity assessment","author":"IJ Dahabreh","year":"2017","unstructured":"Dahabreh IJ, Chan JA, Earley A, Moorthy D, Avendano EE, Trikalinos TA, et al. AHRQ methods for effective health care. Modeling and simulation in the context of health technology assessment: review of existing guidance, future research needs, and validity assessment. Rockville: Agency for Healthcare Research and Quality (US); 2017."},{"key":"1666_CR15","unstructured":"Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Version 5.0. 2016. https:\/\/pbac.pbs.gov.au\/information\/about-the-guidelines.html. Accessed 4 Feb 2026."},{"key":"1666_CR16","unstructured":"National Institute for Health and Care Excellence (NICE). NICE technology appraisal and highly specialised technologies guidance: the manual. 2022. https:\/\/www.nice.org.uk\/process\/pmg36. Accessed 4 Feb 2026."},{"key":"1666_CR17","unstructured":"Canada\u2019s Drug Agency (CDA-AMC). Guidelines for the Economic Evaluation of Health Technologies: Canada. 4th ed. 2017. https:\/\/www.cda-amc.ca\/guidelines-economic-evaluation-health-technologies-canada-4th-edition. Accessed 4 Feb 2024."},{"key":"1666_CR18","unstructured":"Zorginstituut Nederland. Guideline for economic evaluations in healthcare. Diemen: Zorginstituut Nederland; 2024. https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2024\/01\/16\/guideline-for-economic-evaluations-in-healthcare. Accessed 4 Feb 2026."},{"key":"1666_CR19","volume-title":"China guidelines for pharmacoeconomic evaluations","author":"A Cp","year":"2025","unstructured":"China Pharmaceutical Association. China guidelines for pharmacoeconomic evaluations. Beijing: China Market Press; 2025."},{"issue":"9","key":"1666_CR20","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40273-016-0410-3","volume":"34","author":"PT de Boer","year":"2016","unstructured":"de Boer PT, Frederix GW, Feenstra TL, Vemer P. Unremarked or unperformed? Systematic review on reporting of validation efforts of health economic decision models in seasonal influenza and early breast cancer. Pharmacoeconomics. 2016;34(9):833\u201345.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"1666_CR21","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40273-019-00844-y","volume":"37","author":"NC B\u00fcy\u00fckkaramikli","year":"2019","unstructured":"B\u00fcy\u00fckkaramikli NC, Rutten-van M\u00f6lken M, Severens JL, Al M. TECH-VER: a verification checklist to reduce errors in models and improve their credibility. Pharmacoeconomics. 2019;37(11):1391\u2013408.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"1666_CR22","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40273-025-01491-2","volume":"43","author":"K Abraham","year":"2025","unstructured":"Abraham K, Corro Ramos I, Braal CL, Feenstra T, Kleijburg A, van Voorn GAK, et al. Under-reporting of validation efforts for health economic models persists despite the availability of validation tools: a systematic review. Pharmacoeconomics. 2025;43(8):849\u201358.","journal-title":"Pharmacoeconomics"},{"key":"1666_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.10.014","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Wang L, Liang Y, Vasan Thakumar A, Hu H, Li Y, et al. A systematic review of the methods and quality of economic evaluations for artificial-intelligence-assisted cancer screening or diagnosis. Value Health. 2025. https:\/\/doi.org\/10.1016\/j.jval.2025.10.014.","journal-title":"Value Health"},{"key":"1666_CR24","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71.","journal-title":"BMJ"},{"key":"1666_CR25","unstructured":"World Bank. Country and lending groups. 2024. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups. Accessed 1 Oct 2025."},{"key":"1666_CR26","unstructured":"American Cancer Society. Cancer Types by System. https:\/\/www.cancer.org\/cancer\/types.html. Accessed 1 Oct 2025."},{"issue":"4","key":"1666_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jval.2022.11.018","volume":"26","author":"M Yang","year":"2023","unstructured":"Yang M, Vioix H, Sachdev R, Stargardter M, Tosh J, Pfeiffer BM, et al. Cost-effectiveness of tepotinib versus capmatinib for the treatment of adult patients with metastatic non-small cell lung cancer harboring mesenchymal-epithelial transition exon 14 skipping. Value Health. 2023;26(4):487\u201397.","journal-title":"Value Health"},{"issue":"2","key":"1666_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40258-022-00771-8","volume":"21","author":"HT Nguyen","year":"2023","unstructured":"Nguyen HT, De Allegri M, Heil J, Hennigs A. Population-level impact of omitting axillary lymph node dissection in early breast cancer women: evidence from an economic evaluation in Germany. Appl Health Econ Health Policy. 2023;21(2):275\u201387.","journal-title":"Appl Health Econ Health Policy"},{"issue":"8","key":"1666_CR29","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1200\/JCO.22.00478","volume":"41","author":"A Vijenthira","year":"2023","unstructured":"Vijenthira A, Kuruvilla J, Crump M, Jain M, Prica A. Cost-effectiveness analysis of frontline polatuzumab-rituximab, cyclophosphamide, doxorubicin, and prednisone and\/or second-line chimeric antigen receptor T-cell therapy versus standard of care for treatment of patients with intermediate- to high-risk diffuse large B-cell lymphoma. J Clin Oncol. 2023;41(8):1577\u201389.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1666_CR30","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jmoldx.2022.04.010","volume":"24","author":"D Zou","year":"2022","unstructured":"Zou D, Ye W, Hess LM, Bhandari NR, Ale-Ali A, Foster J, et al. Diagnostic value and cost-effectiveness of next-generation sequencing-based testing for treatment of patients with advanced\/metastatic non-squamous non-small-cell lung cancer in the United States. J Mol Diagn. 2022;24(8):901\u201314.","journal-title":"J Mol Diagn"},{"issue":"11","key":"1666_CR31","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s40273-021-01068-9","volume":"39","author":"M Dolph","year":"2021","unstructured":"Dolph M, Tremblay G, Leong H. Cost effectiveness of triplet selinexor-bortezomib-dexamethasone (XVd) in previously treated multiple myeloma (MM) based on results from the phase III BOSTON trial. Pharmacoeconomics. 2021;39(11):1309\u201325.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1666_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-025-05589-2","volume":"43","author":"S Negrier","year":"2025","unstructured":"Negrier S, Bonastre J, Colrat F, Teitsson S, Knight C, Ni L, et al. Cost-effectiveness of nivolumab compared with surveillance for adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in France. World J Urol. 2025;43(1):202.","journal-title":"World J Urol"},{"key":"1666_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108697","volume":"207","author":"M Neyt","year":"2025","unstructured":"Neyt M, Luyten J, Desimpel F, Camberlin C, Primus-de Jong C, Verleye L. An economic evaluation of lung cancer screening with low-dose computed tomography in a high-risk population of (ex-)smokers in Belgium. Lung Cancer. 2025;207:108697.","journal-title":"Lung Cancer"},{"issue":"5","key":"1666_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0302548","volume":"19","author":"F Porte","year":"2024","unstructured":"Porte F, Granghaud A, Chang J, Kearney M, Morel A, Plessala I, et al. Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France. PLoS ONE. 2024;19(5):e0302548.","journal-title":"PLoS ONE"},{"issue":"3","key":"1666_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s40261-024-01413-8","volume":"45","author":"D Abushanab","year":"2025","unstructured":"Abushanab D, Mohamed S, Abdel-Latif R, Moustafa DA, Marridi W, Elazzazy S, et al. Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. A cost-effectiveness analysis. Clin Drug Investig. 2025;45(3):151\u201363.","journal-title":"Clin Drug Investig"},{"key":"1666_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1382599","volume":"14","author":"J Tran","year":"2024","unstructured":"Tran J, Hathaway CL, Broshkevitch CJ, Palanee-Phillips T, Barnabas RV, Rao DW, et al. Cost-effectiveness of single-visit cervical cancer screening in KwaZulu-Natal, South Africa: a model-based analysis accounting for the HIV epidemic. Front Oncol. 2024;14:1382599.","journal-title":"Front Oncol"},{"key":"1666_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13222929","author":"M Lloyd","year":"2025","unstructured":"Lloyd M, Sloan EK, Marquina C, Bouttell J, Hassanien O, Botteri E, et al. Preliminary cost-effectiveness of re-purposing \u03b2-blockers as an adjunct treatment for women with triple-negative breast cancer. Healthcare (Basel). 2025. https:\/\/doi.org\/10.3390\/healthcare13222929.","journal-title":"Healthcare (Basel)"},{"issue":"1","key":"1666_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/JU.0000000000002953","volume":"209","author":"V Sharma","year":"2023","unstructured":"Sharma V, Wymer KM, Joyce DD, Moriarty J, Khanna A, Borah BJ, et al. Cost-effectiveness of adjuvant pembrolizumab after nephrectomy for high-risk renal cell carcinoma: insights for patient selection from a Markov model. J Urol. 2023;209(1):89\u201398.","journal-title":"J Urol"},{"issue":"5","key":"1666_CR39","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s41669-024-00503-9","volume":"8","author":"DB Bayani","year":"2024","unstructured":"Bayani DB, Lin YC, Nagarajan C, Ooi MG, Tso ACY, Cairns J, et al. Modeling first-line daratumumab use for newly diagnosed, transplant-ineligible, multiple myeloma: a cost-effectiveness and risk analysis for healthcare payers. PharmacoEconomics Open. 2024;8(5):651\u201364.","journal-title":"PharmacoEconomics Open"},{"issue":"1","key":"1666_CR40","doi-asserted-by":"publisher","first-page":"2464781","DOI":"10.1080\/20523211.2025.2464781","volume":"18","author":"Y Ding","year":"2025","unstructured":"Ding Y, Wang C, Shu Y, Wang J, Zhang Q. Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial. J Pharm Policy Pract. 2025;18(1):2464781.","journal-title":"J Pharm Policy Pract"},{"key":"1666_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1628024","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Lu Y, Lu Y, Zhou M, Xie X, Zhou Y, et al. Cost-effectiveness of rilertinib versus osimertinib in second-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China. Front Pharmacol. 2025;16:1628024.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1666_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40487-024-00311-5","volume":"13","author":"BJ Monk","year":"2025","unstructured":"Monk BJ, van Mens S, Hale O, Boer J, van Hees F, Swami S, et al. Cost-effectiveness of pembrolizumab as first-line treatment in patients with persistent, recurrent, or metastatic cervical cancer in the United States. Oncol Ther. 2025;13(1):85\u201398.","journal-title":"Oncol Ther"},{"key":"1666_CR43","volume":"62","author":"J Liu","year":"2025","unstructured":"Liu J, Jiao Y, Huang Y, Zhan Y, Shi R, Ruan X, et al. Cost-effectiveness analysis of prostate-specific antigen screening in China: a middle-income population-based microsimulation study. Lancet Reg Health West Pac. 2025;62:101683.","journal-title":"Lancet Reg Health West Pac"},{"issue":"8","key":"1666_CR44","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s40273-021-01015-8","volume":"39","author":"FOL Nilsson","year":"2021","unstructured":"Nilsson FOL, Asanin ST, Masters ET, Iadeluca L, Almond C, Cooper M, et al. The cost-effectiveness of lorlatinib versus chemotherapy as a second- or third-line treatment in anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in Sweden. Pharmacoeconomics. 2021;39(8):941\u201352.","journal-title":"Pharmacoeconomics"},{"key":"1666_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1400422","volume":"16","author":"G Fang","year":"2025","unstructured":"Fang G, Pi Z, An Y, Cao X, Li W, Zhu X, et al. Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model. Front Pharmacol. 2025;16:1400422.","journal-title":"Front Pharmacol"},{"key":"1666_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244240","author":"LC Burg","year":"2024","unstructured":"Burg LC, Vermeulen RJ, Bekkers RLM, Kruitwagen R, Zusterzeel PLM. The cost-effectiveness of sentinel lymph node mapping in high-risk endometrial cancer. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16244240.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1666_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-17358-0","volume":"23","author":"C Kositamongkol","year":"2023","unstructured":"Kositamongkol C, Kanchanasurakit S, Mepramoon E, Talungchit P, Chaopotong P, Kengkla K, et al. Cost-utility and budget impact analyses of cervical cancer screening using self-collected samples for HPV DNA testing in Thailand. BMC Public Health. 2023;23(1):2413.","journal-title":"BMC Public Health"},{"issue":"1","key":"1666_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/13696998.2025.2604968","volume":"29","author":"N Karim","year":"2025","unstructured":"Karim N, Waterhouse D, Jones S, Stollenwerk B. Cost-effectiveness of sotorasib versus adagrasib in previously treated KRAS G12C-mutated advanced NSCLC: a US healthcare payer perspective. J Med Econ. 2025;29(1):77\u201392.","journal-title":"J Med Econ"},{"issue":"3","key":"1666_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0300327","volume":"19","author":"S Sriphoosanaphan","year":"2024","unstructured":"Sriphoosanaphan S, Pantumongkol W, Kulpeng W, Charonpongsuntorn C, Tanwandee T, Sukeepaisarnjaroen W, et al. Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand. PLoS ONE. 2024;19(3):e0300327.","journal-title":"PLoS ONE"},{"issue":"1","key":"1666_CR50","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ygyno.2021.01.035","volume":"161","author":"LC Burg","year":"2021","unstructured":"Burg LC, Vermeulen RJ, Bekkers RLM, Wijn SRW, Rovers MM, Govers TM, et al. A cost-effectiveness analysis of three approaches for lymph node assessment in patients with low- and intermediate-risk endometrial cancer. Gynecol Oncol. 2021;161(1):251\u201360.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"1666_CR51","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40273-022-01160-8","volume":"40","author":"S Qin","year":"2022","unstructured":"Qin S, Wang X, Li S, Tan C, Zeng X, Luo X, et al. Clinical benefit and cost effectiveness of risk-stratified gastric cancer screening strategies in China: a modeling study. Pharmacoeconomics. 2022;40(7):725\u201337.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"1666_CR52","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1200\/JCO.20.01849","volume":"39","author":"KK Patel","year":"2021","unstructured":"Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-effectiveness of first-line versus second-line use of daratumumab in older, transplant-ineligible patients with multiple myeloma. J Clin Oncol. 2021;39(10):1119\u201328.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1666_CR53","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s40273-021-01028-3","volume":"39","author":"D Stellato","year":"2021","unstructured":"Stellato D, Thabane ME, Chandiwana D, Park J, Delea TE. Cost effectiveness of ribociclib plus a nonsteroidal aromatase inhibitor in pre-\/perimenopausal, HR+ and HER2\u2212 advanced breast cancer: a Canadian healthcare perspective. Pharmacoeconomics. 2021;39(7):853\u201367.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1666_CR54","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jval.2020.10.016","volume":"24","author":"T-A Tai","year":"2021","unstructured":"Tai T-A, Latimer NR, Benedict \u00c1, Kiss Z, Nikolaou A. Prevalence of immature survival data for anti-cancer drugs presented to the National Institute for Health and Care Excellence and impact on decision making. Value Health. 2021;24(4):505\u201312.","journal-title":"Value Health"},{"issue":"7","key":"1666_CR55","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2165\/11316900-000000000-00000","volume":"27","author":"SB Cantor","year":"2009","unstructured":"Cantor SB. Is it time for reporting guidelines for calibration methods? Pharmacoeconomics. 2009;27(7):529\u201331.","journal-title":"Pharmacoeconomics"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01666-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01666-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01666-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:17:54Z","timestamp":1789492674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01666-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":55,"alternative-id":["1666"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01666-5","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the data supporting the findings of this study (i.e., the information extracted from the studies included in this review) are available within the article and the Electronic Supplementary Material.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PL and MZ contributed equally to this work. PL: conceptualization; methodology; data curation; data interpretation; visualization; writing\u2014original draft; writing\u2014review and editing. MZ: formal analysis; data interpretation; writing\u2014original draft. HL: conceptualization; supervision; project administration; writing\u2014review and editing. YT: information extraction. HY and HS: data organization; supplementary table preparation. All authors reviewed and approved the final manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}